3-MeO-PCMo
| Summary sheet: 3-MeO-PCMo |
| 3-MeO-PCMo | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||||||||||||||||||
| Chemical Nomenclature | |||||||||||||||||||||||||||||||
| Substitutive name | 3-MeO-PCMo | ||||||||||||||||||||||||||||||
| Systematic name | 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine | ||||||||||||||||||||||||||||||
| Class Membership | |||||||||||||||||||||||||||||||
| Psychoactive class | Dissociative | ||||||||||||||||||||||||||||||
| Chemical class | Arylcyclohexylamine | ||||||||||||||||||||||||||||||
| Routes of Administration | |||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
| Interactions | |||||||||||||||||||||||||||||||
| Stimulants | |||||||||||||||||||||||||||||||
| Depressants | |||||||||||||||||||||||||||||||
3-MeO-PCMo (4-[1-(3-methoxyphenyl)cyclohexyl]morpholine) is a new morpholine analogue of 3-MeO-PCP. It is a dissociative NMDA receptor antagonist, sigma receptor[1] agonist and anesthetic drug of the arylcyclohexylamine chemical class with a potency of less than 1/10th of that of 3-MeO-PCP.
This compound induces a state referred to as "dissociative anesthesia" when ingested and is therefore used as a recreational drug. 3-MeO-PCMo has recently become easily accessible through online research chemical vendors[2] where it is being sold as a designer drug.
Although very little is known about this compound, similar morpholine analogues of phencyclidine have been researched before.[3][4]
Chemistry
3-MeO-PCMo, or 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine, is classified as an arylcyclohexylamine drug. Ayrlcyclohexylamine drugs are named for their structures which include a cyclohexane ring bound to an aromatic ring along with an amine group at the same location. The aryl substituent of 3-MeO-PCMo is a phenyl ring with a methoxy (CH3-O-) substituent at R3, which is bound to a six-membered cyclohexyl ring. Bound at the same location on the cyclohexyl ring R1 is an amine group which is incorporated into a morpholine ring as R4.
Morpholine is a six-membered heterocyclic ring with an oxygen subsitutent at R1. 3-MeO-PCMo is a morpholine analogue to 3-MeO-PCP, which lacks an oxygen moiety in its six-membered amine ring (a piperidine ring instead of a morpholine ring).
Pharmacology
Due to the lack of research regarding the substance, all discussion regarding the pharmacology of it is purely based on its structure and subjective effect similarities to other arylcyclohexylamine dissociatives such as 3-MeO-PCP, PCP and MXE. With this in mind, 3-Meo-PCMo is thought to act as an NMDA receptor antagonist. NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually this substance's equivalent of the “K-hole.”
Subjective effects
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects 
-
- Nausea - It's worth noting that high dose 3-MeO-PCMo trips can sometimes result in nausea and vomiting at the peak of the trip. For most people, this is surprisingly not as unpleasant as they would initially expect due to the accompanying detachment from the physical senses.
- Motor control loss - A loss of gross and fine motor control alongside of balance and coordination is prevalent within 3-MeO-PCMo and becomes especially strong at higher doses. This means that one should be sitting down before the onset (unless experienced) in case of falling over and injuring oneself.
- Perception of bodily lightness - This creates the sensation that the body is floating and has become entirely weightless. This effect is strangely stimulating and encourages physical activities at low to moderate doses by making the body feel light and effortless to move.
- Physical autonomy
- Physical euphoria
- Spatial disorientation
- Spontaneous physical sensations - The 3-MeO-PCMo "body high" is a soft, warm, motionless and pleasurable tingling sensation which is all-encompassing across the body and not location specific to any area.
- Tactile disconnection
- Tactile suppression
Visual effects 
-
Suppression
- Double vision - This component is prevalent at moderate to heavy doses and makes reading impossible unless one closes an eye.
- Frame rate suppression
- Pattern recognition suppression - This effect generally occurs at higher doses and makes one unable to recognize and interpret perceivable visual data.
- Visual acuity suppression
- Visual disconnection - This eventually results in the 3-MeO-PCMo equivalent of the famous "k-hole" or, more specifically, holes, spaces and voids alongside of structures.
Distortions
Geometry
The visual geometry found within 3-MeO-PCMo can be described as very dark and bland when compared to that of ketamine or DXM. It often consists of many tiny interlocking and woven lines. It does not extend beyond level 4 geometry and can be comprehensively described through its variations as simplistic in complexity, algorithmic in style, synthetic in feel, unstructured in organization, dimly lit in lighting, multicoloured in scheme, glossy in shading, soft in edges, small in size, slow in speed, smooth in motion, equal in rounded and angular corners, immersive in depth and consistent in intensity.
Cognitive effects 
-
The general head space of 3-MeO-PCMo is often described as simplistic and shallow in comparison to that of MXE and ketamine. The specific cognitive effects can be broken down into several separate subcomponents which are listed and described below:
- Amnesia
- Anxiety suppression
- Consciousness disconnection
- Compulsive redosing
- Conceptual thinking
- Creativity enhancement
- Déjà vu
- Depersonalization
- Derealization
- Disinhibition
- Dream potentiation
- Existential self-realization
- Euphoria
- Memory suppression
- Immersion enhancement
- Increased music appreciation
- Analysis suppression
- Introspection
- Mania
- Time distortion
- Thought deceleration
Auditory effects 
Experience reports
Anecdotal reports which describe the effects of this compound within this experience index include:
Additional experience reports can be found here:
Potentially dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- Stimulants - Both stimulants and dissociatives carry the risk of adverse psychological reactions like anxiety, mania, delusions and psychosis and these risks are exacerbated when the two substances are combined.
- Depressants - Because both depress the respiratory system, this combination can result in an increased risk of suddenly falling unconscious, vomiting and choking to death from the resulting suffocation. If nausea or vomiting occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
Toxicity and harm potential
The toxicity and long-term health effects of recreational 3-MeO-PCMo use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 3-MeO-PCMo has very little history of human usage. Anecdotal evidence from people who have tried 3-MeO-PCMo within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance to ensure the administration of the intended dose.
Tolerance and addiction potential
As with other NMDA receptor antagonists, the chronic use of 3-MeO-PCMo can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.
Tolerance to many of the effects of 3-MeO-PCMo develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 3-MeO-PCMo presents cross-tolerance with all dissociatives, meaning that after the consumption of 3-MeO-PCMo all dissociatives will have a reduced effect.
Dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- Psychedelics - This combination is not advised because 3-MeO-PCE has been reported to cause extreme psychological disturbances such as psychosis and mania at a significantly higher rate than other dissociatives.
- Stimulants - Both stimulants and dissociatives carry the risk of adverse psychological reactions like anxiety, mania, delusions and psychosis and these risks are exacerbated when the two substances are combined.
- Depressants - Because both depress the respiratory system, this combination can result in an increased risk of suddenly falling unconscious, vomiting and choking to death from the resulting suffocation. If nausea or vomiting occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
Urinary tract effects
In terms of its long-term health effects when used repeatedly and with excess for extended periods of time, 3-MeO-PCMo seems to exhibit almost identical bladder and urinary tract problems to those found within ketamine, MXE and other arylcyclohexylamines, but to an even more extreme extent. This is because 3-MeO-PCMo is 50% less potent than that of ketamine which means significantly more of the drug must be consumed in order to achieve the same effects. Symptoms of 3-MeO-PCMo-induced cystitis can become extremely serious and can be described as:
- Urinary frequency - Urinary frequency is the need to empty the bladder every few minutes.
- Urinary urgency - This can be described as a sudden and compelling need to urinate.
- Urinary pressure - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
- Pelvic and bladder pain - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
- Hematuria - Hematuria is visible blood in the urine.
- Incontinence - This is the leakage of urine.
All of these, however, can easily be avoided by simply not using 3-MeO-PCMo on a daily or even weekly basis and manually limiting one's usage of the substance.
Legal status
 |
This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it. |
3-MeO-PCMo is currently thought to be a legal grey area drug worldwide and is easily accessible through the use of online research chemical vendors. However, this does not guarantee anyone to be immune from legal prosecution should they be found in possession of this substance as the legality is likely to vary from country to country.
- Germany: 3-MeO-PCMo is controlled under the NpSG (New Psychoactive Substances Act)[5] as of July 18, 2019.[6] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[7]
- Switzerland: 3-MeO-PCMo is a controlled substance specifically named under Verzeichnis E.[8]
- United Kingdom - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.[9] While most arylcyclohexylamines are covered by a generic clause[10], the 1-morpholine group of 3-MeO-PCMo is outside of the definition. While the drug is still controlled under the Psychoactive Substances Act, simple possession (other than within a custodial institution) is not criminalised.
See also
External links
References
- ↑ Su, T. P., Wu, X. Z., Cone, E. J., Shukla, K., Gund, T. M., Dodge, A. L., Parish, D. W. (November 1991). "Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand". The Journal of Pharmacology and Experimental Therapeutics. 259 (2): 543–550. ISSN 0022-3565.
- ↑ Ahmadi, A., Khalili, M., Hajikhani, R., Naserbakht, M. (April 2011). "New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats". Pharmacology, Biochemistry, and Behavior. 98 (2): 227–233. doi:10.1016/j.pbb.2010.12.019. ISSN 1873-5177.
- ↑ Ahmadi, A., Khalili, M., Hajikhani, R., Naserbakht, M. (2011). "Synthesis and determination of acute and chronic pain activities of 1-[1-(4-methylphenyl) (cyclohexyl)] morpholine as a new phencyclidine derivative in rats". Arzneimittel-Forschung. 61 (2): 92–97. doi:10.1055/s-0031-1296173. ISSN 0004-4172.
- ↑ Overton, D. A., Shen, C. F., Ke, G. Y., Gazdick, L. P. (1989). "Discriminable effects of phencyclidine analogs evaluated by multiple drug (PCP versus OTHER) discrimination training". Psychopharmacology. 97 (4): 514–520. doi:10.1007/BF00439557. ISSN 0033-3158.
- ↑ "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- ↑ "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
- ↑ "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
- ↑ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
- ↑ Psychoactive Substances Act 2016
- ↑ The Misuse of Drugs Act 1971 (Amendment) Order 2013